1. Home
  2. Labeler Index
  3. Abbvie Srl
  4. 62526-2041
  5. NDC Package Code: 62526-2041-2 Risankizumab-rzaa

NDC Package 62526-2041-2 Risankizumab-rzaa

Kit - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
62526-2041-2
Package Description:
1 KIT in 1 CARTON * .83 mL in 1 SYRINGE * 1 mL in 1 PACKET
Product Code:
62526-2041
Non-Proprietary Name:
Risankizumab-rzaa
Usage Information:
This medication is used to treat plaque psoriasis. Risankizumab-rzaa belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.
11-Digit NDC Billing Format:
62526204102
Product Type:
Drug For Further Processing
Labeler Name:
Abbvie Srl
Dosage Form:
Kit - A packaged collection of related material.
Sample Package:
N/A
Marketing Category:
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date:
04-16-2019
Listing Expiration Date:
12-31-2024
Exclude Flag:
N
Unfinished Product:
Yes
Code Structure:

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 62526-2041-2?

The NDC Packaged Code 62526-2041-2 is assigned to an UNFINISHED drug package of 1 kit in 1 carton * .83 ml in 1 syringe * 1 ml in 1 packet of Risankizumab-rzaa, drug for further processing labeled by Abbvie Srl. The product's dosage form is kit and is administered via form.

Is NDC 62526-2041 included in the NDC Directory?

Yes, Risankizumab-rzaa is an UNFINISHED PRODUCT with code 62526-2041 that is active and included in the NDC Directory. The product was first marketed by Abbvie Srl on April 16, 2019 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

What is the 11-digit format for NDC 62526-2041-2?

The 11-digit format is 62526204102. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-4-1 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
5-4-162526-2041-25-4-262526-2041-02